HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
HCW Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
HCW Biologics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Market Cap | $2.26M | $166.30M |
| Enterprise Value | $8.08M | $88.19M |
| PS Ratio | 0.34 | 3.65 |
| PB Ratio | 0.30 | 2.03 |
| P/TBV Ratio | 0.30 | 2.29 |
Enterprise value
| Measure | HCW Biologics | Industry median |
|---|---|---|
| EV / Sales | 1.21 | 2.51 |
Income (trailing twelve months)
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Revenue | $6.66M | $58.34M |
| Gross Profit | $6.45M | $105.94M |
| Operating Income | -$7.68M | -$21.40M |
| Net Income | -$5.58M | -$22.46M |
| EBITDA | -$7.08M | -$16.91M |
| EPS (Diluted) | -$28.41 | -$0.83 |
Margins
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Gross Margin | 96.7% | 52.9% |
| Operating Margin | -115.3% | -44.0% |
| Profit Margin | -83.8% | -40.2% |
| EBITDA Margin | -106.3% | -30.2% |
Returns
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -151.4% | -53.2% |
| Return on Assets (ROA) | -20.1% | -40.9% |
| Return on Invested Capital (ROIC) | -70.7% | -32.4% |
| Return on Capital Employed (ROCE) | -94.6% | -38.1% |
Growth
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 700.2% | 5.96% |
| Revenue Growth (3Y CAGR) | -79.9% | 2.25% |
| Revenue Growth (5Y CAGR) | -57.9% | 6.48% |
Balance sheet
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $741.32K | $61.43M |
| Total Debt | $6.56M | $118.52M |
| Net Cash (Debt) | -$5.82M | $15.35M |
| Net Cash Per Share | -$3.17 | $0.66 |
| Equity (Book Value) | $7.43M | $49.09M |
| Book Value Per Share | $4.04 | $1.37 |
| Tangible Book Value | $7.43M | $23.52M |
| Working Capital | -$17.51M | $76.81M |
Financial position
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Current Ratio | 0.06 | 3.34 |
| Quick Ratio | 0.04 | 2.44 |
| Debt / Equity | 0.88 | 0.52 |
| Interest Coverage | -14.00 | -6.26 |
Cash flow (trailing twelve months)
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.14M | -$12.35M |
Efficiency
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Asset Turnover | 0.24 | 0.39 |
Dividends and yields
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Earnings Yield | -247.1% | -23.3% |
Shares
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Shares Outstanding | 1,836,320 | 58,127,000 |
| Shares Change (YoY) | 289.0% | 10.9% |
| Float | 1,195,190 | 49,136,700 |
| Shares Held by Insiders | 34.9% | 11.6% |
| Shares Held by Institutions | 5.64% | 59.4% |
Scores
| Measure | HCW Biologics | Industry median |
|---|---|---|
| Altman Z-Score | -7.18 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from HCW Biologics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.